<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>CYB5D2 Requires Heme-Binding Regulate HeLa Cell <br /> Growth Confer Survival Chemotherapeutic <br /> Agents <br /> Anthony Bruce1,2,3*, Adrian P. Rybak1,2,3* <br /> 1 Medical Sciences Program, Faculty Health Sciences, McMaster University, Hamilton, Ontario, Canada, 2 Father Sean O&#8217;Sullivan Research Institute, Hamilton, Ontario, <br /> Canada, 3 Hamilton Centre Kidney Research (HCKR), St. Joseph&#8217;s Hospital, Hamilton, Ontario, Canada <br />  <br />  <br />  <br />      Abstract <br />      The cytochrome b5 domain containing 2 (CYB5D2; Neuferricin) protein reported bind heme, however, the <br />      critical residues responsible heme-binding undefined. Furthermore, relationship heme-binding and <br />      CYB5D2-mediated intracellular functions remains unknown. Previous studies examining heme-binding cytochrome <br />      b5 heme-binding domain-containing proteins, damage-associated protein 1 (Dap1; <span id='am-29' about='obo:NCBITaxon_4932' typeof='owl:Thing obo:NCBITaxon_4930 obo:NCBITaxon_1 obo:NCBITaxon_4751 obo:NCBITaxon_131567 obo:NCBITaxon_4893 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_4892 obo:NCBITaxon_4891 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_147537 obo:NCBITaxon_2759'><span id='am-30' property="oboInOwl:hasExactSynonym" content="lager beer yeast" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasRelatedSynonym" content="Saccharomyes cerevisiae" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasRelatedSynonym" content="Saccaromyces cerevisiae" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-35' property="oboInOwl:hasExactSynonym" content="brewer&apos;s yeast" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces oviformis" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces italicus" datatype="xsd:string"></span><span id='am-38' property="rdfs:label" content="Saccharomyces cerevisiae" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces capensis" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasExactSynonym" content="yeast" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasExactSynonym" content="baker&apos;s yeast" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasRelatedSynonym" content="Sccharomyces cerevisiae" datatype="xsd:string"></span><span id='am-43' property="oboInOwl:hasRelatedSynonym" content="Saccharomyces uvarum var. melibiosus" datatype="xsd:string"></span><span id='am-44'  ></span><span id='am-45' property="oboInOwl:hasRelatedSynonym" content="Candida robusta" datatype="xsd:string"></span>Saccharomyces cerevisiae</span>) human <br />      progesterone receptor membrane component 1 (PGRMC1), revealed conserved tyrosine (Y) 73, Y79, aspartic acid <br />      (D) 86, Y127 residues present human CYB5D2 involved heme-binding. CYB5D2 binds type b heme, <br />      however, substitution <span id='am-7' about='obo:NCBITaxon_3846' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3814 obo:NCBITaxon_1 obo:NCBITaxon_72025 obo:NCBITaxon_131567 obo:NCBITaxon_3803 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_163735 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-8' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-10'  ></span><span id='am-11' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>glycine</span> (G) D86 (D86G) cytochrome b5 heme-binding (cyt-b5) domain <br />      abolished heme-binding ability. Both CYB5D2 CYB5D2(D86G) localize endoplasmic reticulum. Ectopic CYB5D2 <br />      expression inhibited cell proliferation anchorage-independent colony growth HeLa cells. Conversely, CYB5D2 <br />      knockdown ectopic CYB5D2(D86G) expression increased cell proliferation colony growth. As PGRMC1 been <br />      reported regulate expression activities cytochrome P450 proteins (CYPs), examined role CYB5D2 in <br />      regulating activities CYPs involved sterol synthesis (CYP51A1) drug metabolism (CYP3A4). CYB5D2 co-localizes <br />      cytochrome P450 reductase (CYPOR), CYB5D2 knockdown reduced lanosterol demethylase (CYP51A1) levels and <br />      rendered HeLa cells sensitive mevalonate. Additionally, knockdown CYB5D2 reduced CYP3A4 activity. Lastly, CYB5D2 <br />      expression conferred HeLa cell survival chemotherapeutic agents (paclitaxel, cisplatin doxorubicin), ability <br />      promote survival dependent heme-binding ability. Taken together, study provides evidence heme- <br />      binding critical CYB5D2 regulating HeLa cell growth survival, endogenous CYB5D2 required to <br />      modulate CYP activities. <br />  <br />   Citation: Bruce A, Rybak AP (2014) CYB5D2 Requires Heme-Binding Regulate HeLa Cell Growth Confer Survival Chemotherapeutic Agents. PLoS <br />   ONE 9(1): e86435. doi:10.1371/journal.pone.0086435 <br />   Editor: Irina V. Lebedeva, Columbia University, United States America <br />   Received October 10, 2013; Accepted December 10, 2013; Published January 22, 2014 <br />   Copyright: &#223; 2014 Bruce, Rybak. <span id='am-61' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-62'  ></span><span id='am-63' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-65' property="rdfs:label" content="This" datatype="xsd:string"></span>This</span> open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Funding: This work supported research funding St. Joseph&#8217;s HealthCare Hamilton (Division Nephrology), Hamilton Centre Kidney Research <br />   (HCKR) McMaster University Hamilton, Ontario, Canada. The funders role study design, <span id='am-132' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-133' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-134'  ></span><span id='am-135' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-136' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>data</span> collection analysis, decision publish, or <br />   preparation manuscript. <br />   Competing Interests: The authors declared competing interests exist. <br />   * E-mail: <span id='am-111' about='obo:NCBITaxon_43722' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_41937 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_23808 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_91836 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-112' property="rdfs:label" content="Brucea" datatype="xsd:string"></span><span id='am-113' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-114' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-115'  ></span><span id='am-116' property="oboInOwl:hasRelatedSynonym" content="Brucea J.F.Mill." datatype="xsd:string"></span>brucea</span>@mcmaster.ca (AB); rybaka@mcmaster.ca (APR) <br />  <br />  <br />  <br /> Introduction                                                                          binding pocket PGRMCI affected mutating two <br />                                                                                       conserved tyrosine (Y107, Y113) residues [8], mutating the <br />    Progesterone receptor membrane component 1 (PGRMC1)                             conserved aspartic acid residue position 120 glycine (D120G) <br /> the extensively investigated member membrane                              PGRMC1 resulted loss heme-binding ability [7]. <br /> associated progesterone receptor (MAPR) <span id='am-53' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-54' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-55' property="rdfs:label" content="family" datatype="xsd:string"></span>family</span>. The PGRMC1                               Cytochrome b5 domain containing 2 (CYB5D2; Neuferricin) <br /> protein reported multiple functions including steroid                      possesses similar structural components PGRMC1, including an <br /> signaling, sterol synthesis, cytochrome P450 activation drug                      amino-terminal transmembrane (TM) domain conserved <br /> metabolism [1&#8211;3]. The yeast homolog PGRMC1, damage                                 cyt-b5 domain [9]. Consistent structural similarities, <br /> associated protein 1 (Dap1), cytochrome b5 heme-binding (cyt-                       human CYB5D2 reported bind heme deletion the <br /> b5) protein, required survival DNA methylating                        cyt-b5 domain (amino acid residues 55&#8211;98) ablated interaction <br /> agent, methyl methane-sulfonate (MMS) [4,5]. Substitution                      [9]. Both proteins 40.4% identical 55.8% similar within <br /> conserved D91 residue G prevents Dap1 association                           cyt-b5 domain [10]. It previously shown that <br /> with heme Dap1(D91G) incapable protecting yeast                        deletion TM domain CYB5D2 abolished perinuclear <br /> MMS-induced toxicity [6].                                                             localization, compromising survival etoposide treatment. <br />    In accordance PGRMC1 containing cyt-b5 domain,                              Furthermore, deletion cyt-b5 domain (amino acid residues <br /> PGRMC1 binds heme association heme contributes                        35&#8211;134) CYB5D2 increased sensitivity HeLa cells to <br /> to function [7]. UV-visible absorption <span id='am-121' about='obo:NCBITaxon_1118549' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_8936 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_57387 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-122' property="rdfs:label" content="Electron" datatype="xsd:string"></span><span id='am-123' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-124'  ></span><span id='am-125' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>electron</span> paramag-                      etoposide toxicity [10]. <br /> netic resonance (ESR) spectra used demonstrate                              Cytochrome b5 heme-binding (cyt-b5) domain-containing <br /> PGRMC1 binds b-type heme [8]. The hydrophobic heme-                                proteins shown bind regulate cytochrome <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                        1                               January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                             CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br /> P450 (CYP) proteins, heme-dependent monooxygenases                       <span id='am-117' about='obo:NCBITaxon_29278' typeof='owl:Thing obo:NCBITaxon_81077 obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-118' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-119' property="rdfs:label" content="vectors" datatype="xsd:string"></span><span id='am-120' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Vectors</span> expressing amino-terminal glutathione S-transferase <br /> participate xenobiotic detoxification, sterol steroid biosyn-        (GST) fusion proteins, GST-CYB5D2 GST-CYB5D2(D86G), <br /> thesis, metabolism pharmaceutical drugs [11]. Dap1,                produced insertion CYB5D2(DTM) and <br /> heme-binding protein <span id='am-46' about='obo:NCBITaxon_4930' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_4893 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_4892 obo:NCBITaxon_4891 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_2759 obo:NCBITaxon_147537'><span id='am-47' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="Saccharomyces" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasAlternativeId" content="NCBITaxon:36915" datatype="xsd:string"></span><span id='am-50'  ></span><span id='am-51' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:hasRelatedSynonym" content="Pachytichospora" datatype="xsd:string"></span>Saccharomyces</span> cerevisiae, initially shown       CYB5D2(D86G-DTM) pGEX2T. Primers PCR condi- <br /> to target stabilize CYP protein, Cyp51A1 (Erg11) [5,6],             tions used construct CYB5D2 mutants summarized Table <br /> and shown bind positively regulate Cyp51A1               S1. <br /> Cyp61A1 (Erg5) [12]. The ability Dap1 regulate Cyp51A1 <br /> activity shown occur heme-dependent fashion                Purification GST-CYB5D2 GST-CYB5D2(D86G) <br /> [6,12]. Human PGRMC1 shown bind CYP51A1                            Fusion proteins GST-CYB5D2 GST-CYB5D2(D86G) <br /> (lanosterol demethylase), loss PGRMC1 reducing                      produced BL-21 <span id='am-88' about='obo:NCBITaxon_562' typeof='owl:Thing obo:NCBITaxon_561 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-89' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-90' property="rdfs:label" content="Escherichia coli" datatype="xsd:string"></span><span id='am-91' property="oboInOwl:hasRelatedSynonym" content="Escherchia coli" datatype="xsd:string"></span><span id='am-92' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662104" datatype="xsd:string"></span><span id='am-93' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli" datatype="xsd:string"></span><span id='am-94' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-95' property="oboInOwl:hasDbXref" content="PMID:10319482" datatype="xsd:string"></span><span id='am-96' property="oboInOwl:hasRelatedSynonym" content="Enterococcus coli" datatype="xsd:string"></span><span id='am-97'  ></span><span id='am-98' property="oboInOwl:hasRelatedSynonym" content="bacterium E3" datatype="xsd:string"></span><span id='am-99' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662101" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli commune" datatype="xsd:string"></span><span id='am-101' property="oboInOwl:hasRelatedSynonym" content="Eschericia coli" datatype="xsd:string"></span><span id='am-102' property="oboInOwl:hasRelatedSynonym" content="Bacillus coli" datatype="xsd:string"></span><span id='am-103' property="oboInOwl:hasExactSynonym" content="Escherichia/Shigella coli" datatype="xsd:string"></span>Escherichia coli</span> host using the <br /> CYP51A1 activity, impairing cholesterol synthesis resulting             pGEX2T/GST-CYB5D2 pGEX2T/GST-CYB5D2(D86G) <br /> in elevated lanosterol levels [12,13]. In addition, PGRMC1              vectors following published conditions [14]. Thrombin (Sigma- <br /> been shown bind CYP enzymes (CYP3A4, CYP21A2,                      Aldrich) used concentration 1.5 mg/ml cleave <br /> CYP7A1, CYP2C2 CYP2C8) [12,13], activities                  1 mg purified GST-CYB5D2 GST-CYB5D2(D86G) <br /> CYP2C2 drug metabolizing P450 cytochromes (CYP3A4                   protein present thrombin cleavage buffer [0.05 M Tris <br /> CYP2C8) modestly affected human embryonic kidney                   (pH 7.5), 0.15 M NaCl2, 2.5 mM CaCl2]. Thrombin cleavage was <br /> (HEK293) HepG2 liver cells [13]. Furthermore, heme-                 performed room temperature 6 hours (h) <span id='am-71' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-72' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-73' property="rdfs:label" content="order" datatype="xsd:string"></span>order</span> cleave <br /> binding defective mutant, PGRMC1(D120G), reduced                        recombinant GST CYB5D2 CYB5D2(D86G) <br /> survival MDA-MB-231 breast <span id='am-56' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-57' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-58' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-60'  ></span>cancer</span> cells doxorubicin                 fusion proteins. GST-agarose subsequently used GST <br /> and camptothecin [7], implicating heme-binding capacity              removal. The recombinant GST-free CYB5D2 and <br /> PGRMC1 regulating susceptibility chemotherapeutic                CYB5D2(D86G) proteins confirmed Western blot using <br /> agents.                                                                     in-house generated anti-CYB5D2 rabbit polyclonal antibody <br />     In current study, demonstrate mutating                  [10]. <br /> conserved aspartic acid residue position 86 (D86) the <br /> cyt-b5 domain CYB5D2 ablates heme-binding ability, but <br /> does affect endoplasmic reticulum (ER) localization. This <br />                                                                             Analysis Heme-binding Ability CYB5D2 <br />                                                                                Association CYB5D2 heme/hemin determined by <br /> heme-binding defective mutant (D86G) precipitate with <br /> hemin-agarose, unlike wild-type CYB5D2. Furthermore,                    methods. An vector (pcDNA3.0) pcDNA3- <br /> CYB5D2(D86G) mutant oxidized reduced vitro,                 based vectors expressing amino-terminal FLAG-tagged CYB5D2, <br /> unlike wild-type CYB5D2. While CYB5D2 expression inhibited                  CYB5D2(Y73A), CYB5D2(Y79A), CYB5D2(D86G), CY- <br /> HeLa cell proliferation colony growth soft agar,                 B5D2(Y127A) transiently expressed 293T cells following <br /> CYB5D2(D86G) mutant increased proliferation anchor-                 calcium phosphate transfection, allowed express 48 h. <br /> age-independent growth HeLa cells. Similarly, knockdown               Cell lysates prepared buffer containing 20 mM Tris <br /> CYB5D2 increased HeLa cell proliferation soft agar colony               (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton <br /> growth. Therefore, loss heme-binding ability results CYB5D2           X-100, 25 mM sodium pyrophosphate, 1 mM NaF, 1 mM b- <br /> &#8216;&#8216;loss function&#8217;&#8217;, affect putative tumor              glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF, <br /> suppressor role. In addition, CYB5D2 co-localizes cyto-                2 mg/ml leupeptin 10 mg/ml aprotinin. Hemin-agarose <br /> chrome P450 reductase (CYPOR), microsomal protein required                (Sigma-Aldrich) slurry washed times co-immuno- <br /> for cytochrome P450 (CYP) protein activation. Moreover, loss             precipitation buffer containing 0.1% Triton, 150 mM NaCl, <br /> endogenous CYB5D2 reduced activity CYP proteins                      5 mM EDTA 50 mM Tris (pH 7.5), followed incubation <br /> involved sterol synthesis (CYP51A1) drug metabolism                  pre-washed hemin-agarose slurry (20 ml) 100 mg cell <br /> (CYP3A4). Finally, knockdown CYB5D2 ectopic expres-                  lysate 4uC overnight rotation. Hemin-agarose containing <br /> sion heme-binding defective CYB5D2(D86G) increased                   lysates washed 1 ml co-immunoprecipitation buffer <br /> susceptibility HeLa cells paclitaxel, cisplatin doxorubicin       times prior Western blot analysis indicated <br /> treatment. Taken together, heme-binding CYB5D2 required               antibodies. <br /> for cell growth conferring survival chemotherapeutic                  GST-CYB5D2 GST-CYB5D2(D86G) (200 mg) re- <br /> agents, endogenous CYB5D2 necessary modulate                  suspended 200 mM NaOH 40% pyridine solution, to <br /> CYP activities.                                                             3 ml 0.1 M K3Fe(CN)6 added [15]. Protein solutions <br />                                                                             (at final concentration 200 mg/ml) measured for <br /> Materials Methods                                                       absorbance scanning 350&#8211;490 nm wavelength 1 nm <br />                                                                             increments using PRISM software Ultraspec2100 spectro- <br /> Cell Lines <span id='am-137' about='obo:NCBITaxon_36549' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-138' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-139' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-140' property="rdfs:label" content="plasmids" datatype="xsd:string"></span><span id='am-141' property="oboInOwl:hasAlternativeId" content="NCBITaxon:2435" datatype="xsd:string"></span>Plasmids</span>                                                     photometer (Thermo Fisher Scientific). <br />    HeLa 293T cells purchased American Type                       Heme-bound GST-CYB5D2 assayed in-gel <br /> Culture Collection (ATCC) cultured DMEM supplemented                 peroxidase reaction staining using previously published protocol <br /> with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich)            [16,17]. Briefly, recombinant GST-CYB5D2 GST- <br /> 1% penicillin/streptomycin (Life Technologies) according                 CYB5D2(D86G) (10 mg) incubated hemin (50 mM; <br /> ATCC instructions. Construction vectors expressing amino-                Sigma-Aldrich) room temperature 30 minutes, followed by <br /> terminal HA-tagged CYB5D2, CYB5D2(DTM), CY-                             separation SDS-PAGE addition dithiothreitol <br /> B5D2(Dcyt-b5)            previously   described   [10].            (DTT). The SDS-PAGE gel rinsed 16TBS 5 min, <br /> CYB5D2(D86G), CYB5D2(Y73A), CYB5D2(Y79A), CY-                               followed incubation ECL Western Blotting Detection Kit <br /> B5D2(Y127A) CYB5D2 inserted amino-terminal                      (GE Healthcare) develop signal. Coomassie blue staining of <br /> HA- FLAG-tagged pcDNA3-based vectors. The                          SDS-PAGE gel carried verify equal protein loading. <br /> mentioned mutants generated site-directed mutagenesis <br /> according published methodology [14]. <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              2                         January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                             CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br /> Determination Type Heme Binds                             Plus 5.0 software (MediaCybernetics). Digital images plates <br /> CYB5D2                                                                      taken using Sony Cyber-shot (DSC-W220) digital <span id='am-66' about='obo:NCBITaxon_274080' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_65171 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_7408 obo:NCBITaxon_7401 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_231877 obo:NCBITaxon_172377 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7400 obo:NCBITaxon_33392 obo:NCBITaxon_7399 obo:NCBITaxon_50557'><span id='am-67' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-68' property="rdfs:label" content="Camera" datatype="xsd:string"></span><span id='am-69'  ></span><span id='am-70' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>camera</span> <br />    Recombinant GST-free CYB5D2 CYB5D2(D86G) pro-                        (Sony Corporation) subsequently processed using Corel- <br /> teins dissolved buffer containing 200 mM NaOH, 40%                DRAW Graphics Suite X4 software (Corel). <br /> pyridine 3 ml 0.1 M K3Fe(CN)6 (at final concentration of <br /> 200 mg/ml) determine absorbance spectra oxidizing            Cell Proliferation Assay <br /> conditions. To determine absorbance spectra CYB5D2                      To measure HeLa cell growth, 104 cells seeded triplicate <br /> under reducing conditions, 2.5 mg/ml sodium dithionite (Sigma-              (12-well plates) serum-supplemented DMEM media. Cells were <br /> Aldrich) [9,18] added purified recombinant GST-free                  trypsinized counted haemocytometer using Trypan <br /> CYB5D2 absorbance measured scanning                     blue reagent (Sigma-Aldrich) exclude dead cells. Cells <br /> 350&#8211;490 nm wavelength 1 nm increments (Ultrospec 2100).                  numbers counted daily day 1 day 6. Cell proliferation <br />    Association heme heme-binding protein occurs               assay conducted quadruplicate. <br /> through covalent (type c heme) non-covalent (types or <br /> b heme) interaction [19], oxidized heme-bound (types a, b          Cell Viability Assays <br /> c) proteins distinguished absorbance peaks               Cell viability following chemotherapeutic drug mevalonate <br /> 500&#8211;600 nm range [15]. Under oxidizing conditions, recombinant              treatment measured using Cell Proliferation Kit I (3-[4,5 <br /> GST-free CYB5D2 CYB5D2(D86G) (200 mg/ml) incu-                      dimethylthiazol-2-y]-2,5-diphenyl-tetrazolium bromide; MTT) as- <br /> bated 20 mM hemin [20] absorbance spectra                  say (Roche). For MTT assays, cells seeded density of <br /> recorded scanning 520&#8211;620 nm wavelength 1 nm                     56103 cells 96-well plates 24 h. Cells were <br /> increments (Ultrospec 2100).                                                subsequently treated doxorubicin, cisplatin pacli- <br />                                                                             taxel (Sigma-Aldrich) indicated doses 24 48 h. As a <br /> Virus Production Stable Cell Line Generation                            control, equal volume dimethylsulfoxide (DMSO) was <br />    In order generate HeLa cells stably expressing                        administered stable cell line time point. Following <br /> CYB5D2(D86G), amino-terminal FLAG-tagged CYB5D2(D86G)                       treatment, cell viability measured using MTT assay, <br /> was sub-cloned pLHCX vector. CYB5D2/pLHCX,                         according manufacturer&#8217;s instructions. Absorbance readings <br /> CYB5D2(D86G)/pLHCX vector (EV)/pLHCX con-                         carried SPECTRAmax Plus 384 spectrophotometer <br /> structs co-transfected 293T cells VSV             (Molecular Devices). <br /> and GP retroviral packaging plasmids (Stratagene) using                    For mevalonate treatments, cells seeded density of <br /> calcium phosphate transfection method. Sixty hours post-trans-              56103 cells 96-well plates 24 h, followed by <br /> fection, supernatants containing VSV-G pseudotyped, repli-              aspirating media re-feeding DMEM +5% lipoprotein- <br /> cation-incompetent retroviral particles collected, filtered            deficient serum mevalonate (Sigma-Aldrich) the <br /> through 0.45 mm filter centrifuged 2 h 48,000 g. Viral         indicated concentrations 24 h. Following treatment, cell <br /> pellets resuspended media containing 10 mg/ml polybrene             viability measured using MTT assay. <br /> (Sigma-Aldrich) added cells 2 h, periodic mixing at <br /> 20 min intervals, allow cell infection. Infection selected       Cytochrome P450 3A4 Activity Assay <br /> in hygromycin (0.5 mg/ml; Life Technologies) generate stable                Cytochrome P450 (CYP) 3A4 activity measured using the <br /> cell lines.                                                                 CYP3A4 P450-GloTM assay (with Luciferin-IPA) (Promega) as <br />    CYB5D2 shRNA (shCYB5D2) non-specific shRNA control                   previously described [13]. Briefly, HeLa cell lines seeded a <br /> (shCTRL) lentiviral pool plasmids purchased Santa                 density 26104 cells/well 12-well plates (Sarstedt Inc.). <br /> Cruz Biotechnology Inc., packaged 293T cells co-                  Twenty-four hours later, 0.5 mg CYPOR-YFP plasmid (kindly <br /> transfecting shRNA plasmid pool (10 mg) plasmids                  provided Dr. Byron Kemper, University Illinois, USA) was <br /> (10 mg each) necessary third-generation lentiviral production           transfected cells using Lipofectamine 2000 reagent (Life <br /> (pRSV-REV, pCMV-VSV-G, pMDLg/pRRE) [21], using                          Technologies). Twenty-four hours transfection, cells were <br /> calcium phosphate transfection method. Filter-sterilized (0.45 mm)          washed phosphate-buffered saline fresh media containing <br /> media containing shCYB5D2 shCTRL <span id='am-1' about='obo:NCBITaxon_11646' typeof='owl:Thing obo:NCBITaxon_11632 obo:NCBITaxon_1 obo:NCBITaxon_35268 obo:NCBITaxon_10239 obo:NCBITaxon_327045'><span id='am-2' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="Lentivirus" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasRelatedSynonym" content="Lentivirinae" datatype="xsd:string"></span><span id='am-5'  ></span><span id='am-6' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>lentivirus</span>                        luminogenic substrate (50 mM) added. After 3 h incubation <br /> subsequently concentrated centrifugation 2 h 48,000 g,            period, 100 ml media mixed equal <br /> resuspended 1 ml DMEM media containing polybrene,                 volume Luciferin Detection reagent luminescence was <br /> added HeLa cells 2 h, periodic mixing 20 min                 measured using LUMIstar luminometer (BMG LABTECH). <br /> intervals, allow cell infection. Puromycin (1 mg/ml; Sigma- <br /> Aldrich) subsequently added select infection.                    Immunofluorescence <br />                                                                                Immunofluorescent staining cells performed previously <br /> Anchorage-independent Growth Assay                                          described [22]. Briefly, HeLa cells seeded 8-well chamber <br />   HeLa stable cell lines (EV, CYB5D2, CYB5D2(D86G),                         slides (Thermo Fisher Scientific) 24 h, fixed 4% <br /> shCTRL shCYB5D2) dissociated trypsinization,                    paraformaldehyde permeabilized using 0.3% Triton X- <br /> and individualized (56104) cells mixed agarose-                   100 16PBS solution, subsequently incubated mouse <br /> containing media plated 60 mm plates, previously                  anti-FLAG (M2; 1:100, Sigma-Aldrich) rabbit anti-GRP78 <br /> described [22]. Each experiment conducted triplicate. After          (H-129; Santa Cruz Biotechnology) antibodies. For co-staining of <br /> 8 weeks, images taken 10 random fields plate using          CYB5D2 CYPOR, CYB5D2-expressing HeLa cells were <br /> Zeiss Axiovert 200 M microscope (AxioVision 3.1 software)                seeded 60-mm tissue culture plate (Sarstedt) transfected <br /> 25X magnification, colonies consisting $50 cells            CYPOR-YFP plasmid (10 mg) using Lipofectamine 2000 <br /> counted. To determine colony size, images spheres                   reagent (Life Technologies) according manufacturer&#8217;s <br /> captured 50X magnification, mean diameter (in                    instructions. Twenty hours post-transfection, CYPOR-trans- <br /> microns) individual colonies determined using ImagePro               fected cells seeded 8-well chamber slides 24 h later, <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              3                          January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                           CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br /> cells fixed, permeabilized incubated mouse anti-            alignment (Figure 1A). Additionally, D120 residue of <br /> FLAG antibody (M2). Slides subsequently washed 16PBS              PGRMC1 recently reported play major role heme- <br /> solution incubated donkey anti-mouse IgG-FITC,                   binding [7]. This critical heme-binding D120 residue PGRMC1 <br /> donkey anti-rabbit IgG-FITC donkey anti-rabbit IgG-Rhoda-              conserved D86 CYB5D2 (Figure 1A). Furthermore, these <br /> mine secondary antibodies (1:200 dilution; Jackson Laboratories)          residues conserved 1J03 protein. Collectively, our <br /> for 1 h, required. Slides mounted coverslip using          analysis reveals amino acid residues Y73, Y79, D86, and <br /> Vectashield Mounting Medium DAPI (Vector Laboratories,               Y127 human CYB5D2 conserved human PGRMC1, <br /> Inc., H-1200), images captured using Zeiss Axiovert            yeast Dap1, 1J03 protein <span id='am-12' about='obo:NCBITaxon_3701' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_980083 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_3700 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_3699 obo:NCBITaxon_58024 obo:NCBITaxon_91836 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-13' property="oboInOwl:hasRelatedSynonym" content="Cardaminopsis" datatype="xsd:string"></span><span id='am-14'  ></span><span id='am-15' property="oboInOwl:hasAlternativeId" content="NCBITaxon:45250" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="Arabidopsis" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Arabidopsis</span> thaliana (Figure 1A). <br /> 200 M inverted fluorescence microscope using AxioVision 3.1 <br /> software. Images processed using ImageJ software (version            Characterization CYB5D2-mediated Heme Association <br /> 1.43 u; W. Rasband, National Institute Health).                           As conserved residues (Y73, Y79, D86, Y127) have <br />                                                                           reported contribute heme association PGRMC1 and <br /> Western Blot Analysis                                                     Dap1, hypothesized play role CYB5D2- <br />    Whole cell homogenate lysates prepared buffer                mediated heme-binding. To examine possibility, individ- <br /> containing 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA,                   ually replaced tyrosine residues alanine (Y73A, <br /> 1 mM EGTA, 1% Triton X-100, 25 mM sodium pyrophosphate,                   Y79A, Y127A), conserved D86 glycine (D86G). <br /> 1 mM NaF, 1 mM b-glycerophosphate, 0.1 mM sodium ortho-                   Substitution glycine (G) D86 CYB5D2 carried in <br /> vanadate, 1 mM PMSF, 2 mg/ml leupeptin 10 mg/ml                       order generate CYB5D2(D86G) mutant D120G <br /> aprotinin. A total 50 mg cell lysate separated         substitution PGRMC1 [7] D91G Dap1 [6] ablated <br /> SDS-PAGE transferred Immobilon-P membranes                       heme-binding respective proteins. When transiently <br /> (Millipore). Membranes blocked 5% skim milk 16               expressed 293T cells, CYB5D2 mutants expressed <br /> Tris-buffered saline containing 0.1% Tween-20 (TBST) solution             comparable levels wild-type CYB5D2 cell lysates <br /> and incubated indicated antibodies 4uC overnight.        (Figure 1B), suggesting overall configuration folding <br /> Primary antibodies concentrations used follows: anti-         significantly affected aforementioned substitutions. <br /> CYP51A1 (13&#8211;431, 1:1000; Proteintech Group, Inc.), anti-FLAG              While CYB5D2, Y73A, Y79A, Y127A mutants <br /> (M2, 1:1000; Sigma-Aldrich), anti-CYB5D2 (1:200; in-house),               effectively   precipitated      hemin-agarose,      the <br /> anti-HA (12CA5, 1:1000), anti-AKT1 (C-20, 1:1000), anti-b-actin           CYB5D2(D86G) mutant precipitated (Figure 1B, bottom <br /> (C-11, 1:1000), anti-cytochrome P450 reductase (CYPOR) (F-2,              panel). This result demonstrates D86 critical residue <br /> 1:1000), anti-cyclin D1 (H-295, 1:200), anti-GRP78 (N-20, 1:200),         responsible CYB5D2&#8217;s ability bind heme. <br /> anti-p21 (C-19, 1:200), anti-p27 (F-8, 1:200) Santa Cruz                CYB5D2 contains conserved motifs: single transmem- <br /> Biotechnology, anti-IkB-a (#9242, 1:1000), anti-phospho-AKT               brane motif cyt-b5 domain [9]. CYB5D2 mutants with <br /> (Ser473; #4058, 1:1000), anti-phospho-ERK1/2 (Thr202/                     deletion transmembrane domain (TM) cyt-b5 <br /> Tyr204, #9101, 1:1000), anti-ERK1/2 (#9102, 1:1000)                  domain previously generated [10]. To examine the <br /> Cell Signaling Technology. Immunoblot signals detected               contribution TM cyt-b5 domains heme- <br /> using anti-mouse-horse radish peroxidase (HRP) (1:3000, GE                binding ability CYB5D2, mutants successfully <br /> Healthcare), anti-rabbit-HRP (1:3000, GE Healthcare) anti-             expressed 293T cells (Figure S1, panel). These mutants were <br /> goat-HRP (1:3000, Santa Cruz Biotechnology) secondary anti-               subsequently precipitated hemin-agarose (Figure S1, bottom <br /> bodies ECL reagent (GE Healthcare).                                   panel). The CYB5D2(DTM) mutant able precipitate with <br />                                                                           hemin-agarose, demonstrating competency binding heme. <br /> Statistical Analysis                                                      However, CYB5D2(Dcyt-b5) mutant precipitate <br />    Statistical analysis performed using Student&#8217;s t-test (two-        hemin-agarose (Figure S1, panel). Taken together, <br /> tailed independent), p,0.05 considered statistically              observations demonstrate cyt-b5 domain, more <br /> significant.                                                              importantly D86 residue domain, critical for <br />                                                                           heme-binding. <br /> Results <br />                                                                           D86 Residue CYB5D2 Required Heme-binding <br /> Examination cyt-b5 Domain CYB5D2                                   The heme-binding analysis carried following transient <br />    While CYB5D2 shares 19.8% identity 26.2% similarity                expression CYB5D2 mutants 293T cells, coupled <br /> with PGRMC1, homologous region largely centered           hemin-agarose pull-down analysis, does exclude the <br /> cyt-b5 domains 40.4% identical 55.8% similar [10].          possibility D86 residue mediate CYB5D2 associate <br /> Consistent well-documented property cyt-b5 motif          potential heme-binding protein. To eliminate this <br /> in heme association [1], CYB5D2 (Neuferricin) reported             possibility, purified GST-CYB5D2 GST-CYB5D2 <br /> bind heme [9]. Whether association mediated               (D86G) recombinant fusion proteins using BL-21 E. coli host. <br /> specific residues cyt-b5 domain CYB5D2 remains                  To enhance solubility fusion proteins, transmem- <br /> unclear. Upon structural analysis 1J03 protein (homolog         brane domain deleted (DTM). During purification process, <br /> the mammalian membrane-associated progesterone receptor)               observed GST-CYB5D2-bound glutathione-agarose <br /> <span id='am-19' about='obo:NCBITaxon_3702' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_980083 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_3700 obo:NCBITaxon_3701 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_3699 obo:NCBITaxon_58024 obo:NCBITaxon_91836 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-20' property="oboInOwl:hasRelatedSynonym" content="Arabidopsis thaliana (thale cress)" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasExactSynonym" content="mouse-ear cress" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasExactSynonym" content="thale cress" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasExactSynonym" content="thale-cress" datatype="xsd:string"></span><span id='am-25' property="rdfs:label" content="Arabidopsis thaliana" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasRelatedSynonym" content="Arbisopsis thaliana" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-28'  ></span>Arabidopsis thaliana</span> [23,24], revealed key residues       displayed darker brown color compared GST- <br /> structural elements cyt-b5 domain conserved           CYB5D2(D86G)-bound glutathione-agarose (Figure 2A), ob- <br /> PGRMC1 [2]. In researching residues responsible heme-                 servation consistent previously reported recombi- <br /> binding protein family, Y107 Y113 residues human           nant murine Neuferricin (CYB5D2) human PGRMC1 <br /> PGRMC1, Y138 residue Dap1 (the yeast homolog            proteins [7,9]. From respective glutathione-agarose pull-down, <br /> of PGRMC1), contribute heme-binding [8,12,25]. These             GST-CYB5D2 GST-CYB5D2(D86G) recombinant proteins <br /> tyrosine residues conserved CYB5D2 Y73, Y79,                subsequently eluted comparable purity (Figure 2B). <br /> Y127, respectively, determined Clustal Omega (1.2.0)                Heme-associated proteins possess maximal absorbance at <br />  <br />  <br /> PLOS ONE | www.plosone.org                                            4                          January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                               CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 1. The D86 residue CYB5D2 contributes CYB5D2-mediated heme-binding. A) Alignment cyt-b5 domain human <br /> cytochrome b5 domain containing 2 (CYB5D2) protein (amino acid residues (<span id='am-126' about='obo:NCBITaxon_152839' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_158359 obo:NCBITaxon_158331 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158350 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-127' property="rdfs:label" content="Aa" datatype="xsd:string"></span><span id='am-128' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-129' property="oboInOwl:hasRelatedSynonym" content="Aa Rchb.f." datatype="xsd:string"></span><span id='am-130'  ></span><span id='am-131' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>aa</span>.) 38 133), human progesterone receptor membrane component 1 <br /> (PGRMC1; aa. 73 170), damage-associated protein 1 (Dap1) Saccharomyces cerevisiae (aa. 44 144), 1J03 protein (Arabidopsis thaliana; <br /> aa. 5 100) performed using Clustal Omega (1.2.0). Identical residues indicated (*). The D86 residue CYB5D2 conserved D120 <br /> residue PGRMC1 indicated (arrow), conserved tyrosine residues (Y73, Y79, Y127 CYB5D2) previously implicated PGRMC1 and <br /> Dap1 mediated heme-binding [6&#8211;8,12,25]. B) 293T cells transiently transfected vector (EV), CYB5D2, indicated CYB5D2 <br /> mutants. The expression ectopic proteins cell lysates examined Western blot (top panel), ectopic proteins were <br /> precipitated hemin-agarose (bottom panel). Blots probed anti-FLAG (M2) antibody. <br /> doi:10.1371/journal.pone.0086435.g001 <br />  <br /> approximate 402 nm wavelength [7,9]. In accordance                 heme-binding proteins oxidized [15]. While type c heme <br /> property, GST-CYB5D2 protein, GST-CYB5D2(D86G),                      does dissociate cytochrome c, presence protein <br /> displayed peak absorbance approximately 402 nm (Figure 2C).             does interfere heme c oxidization [15]. Oxidised heme a, <br /> This observation confirmed GST-CYB5D2 protein                   b, c display specific spectrum absorbance, peak <br /> associates heme substitution D86 glycine               absorbance types a, b, c 588 nm, 556 nm, and <br /> substantially reduced heme association.                                  550 nm, respectively [15]. To exclude possibility the <br />    To consolidate observation, performed in-            presence GST GST-CYB5D2 fusion affect its <br /> gel peroxidase reaction staining. When loaded heme, heme-               association heme subsequent oxidation, GST <br /> binding proteins detected peroxidase reaction staining             portion recombinant proteins cleaved treating <br /> [9,16,17]. While recombinant GST-CYB5D2(D86G) protein                    thrombin (Figure 3A). When absorbance CYB5D2- <br /> not detected peroxidase reaction staining,               associated heme measured, peak absorbance observed <br /> heme loading, GST-CYB5D2 protein detected                 approximately 559 nm. Under conditions, <br /> heme-loaded condition (Figure 2D). In reactions, heme              CYB5D2(D86G) protein did generate absorbance peak <br /> present excess, comparable amounts free heme                    (Figure 3B). Taken together, observations suggest that <br /> observed reactions GST-CYB5D2+ heme, GST-                       CYB5D2 binds type b heme. <br /> CYB5D2(D86G)+heme, heme (Figure 2D, middle                            To characterize association CYB5D2 and <br /> panel). Therefore, inability detect heme-associated GST-              heme, absorbance thrombin-cleaved CYB5D2 and <br /> CYB5D2(D86G) protein caused insufficient                CYB5D2(D86G) recombinant proteins examined under <br /> of heme present.                                                       oxidized reduced conditions. The GST-free CYB5D2 <br />                                                                              recombinant protein displayed peak absorbance 402 nm <br /> CYB5D2 Binds Type b Heme                                                  (oxidized condition) shifted 420 nm reduced <br />    The heme population consists types a, b, c. While type c           conditions (Figure 3C), typical absorbance pattern heme- <br /> heme covalently links proteins (cytochrome c), types           associated proteins including murine CYB5D2 (Neuferricin) [9]. <br /> b heme attach protein non-covalent bonds [19]. In fact,               The GST-free CYB5D2(D86G) recombinant protein be <br /> cytochrome a, b, c named existence heme            oxidized reduced (Figure 3C). Taken together, above <br /> types a, b, c, respectively. Among types heme, heme          observations reveal D86 residue, present cyt-b5 <br /> b common type [19]. Therefore, existence cyt-           domain, directly responsible CYB5D2 bind heme. <br /> b5 (heme-binding) motif suggests CYB5D2 binds type b heme. <br /> In reaction containing sodium hydroxide, pyridine and <br /> potassium ferricyanide, types b heme associated with <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               5                           January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                          CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 2. D86G substitution renders recombinant CYB5D2 incapable binding heme. A) Images GST-CYB5D2 (CYB5D2)-bound and <br /> GST-CYB5D2(D86G)-bound glutathione-agarose. B) 10 mg purified recombinant GST-CYB5D2 (CYB5D2) GST-CYB5D2(D86G) (CYB5D2(D86G)) <br /> was separated SDS-PAGE, followed Coomassie blue staining. C) Recombinant GST-CYB5D2 GST-CYB5D2(D86G) protein, referred as <br /> CYB5D2 CYB5D2(D86G) respectively, scanned absorbance peaks indicated wavelength range. D) Recombinant GST- <br /> CYB5D2 (CYB5D2) GST-CYB5D2(D86G) (10 mg) incubated hemin analyzed in-gel peroxidase reaction staining detect heme <br /> binding (see Materials Methods technical details). Presence free (unbound) heme detected (middle panel). Equal loading of <br /> recombinant proteins verified Coomassie blue staining (bottom panel). <br /> doi:10.1371/journal.pone.0086435.g002 <br />  <br />  <br /> Heme-binding Contributes CYB5D2-mediated                              stress [26&#8211;28]. This suggests substitution D86 with <br /> Regulation HeLa Cell Proliferation Anchorage-                     glycine CYB5D2 does result protein misfolding. <br /> independent Growth                                                          CYB5D2 (Neuferricin) shown promote neuron <br />    In order examine function CYB5D2                        differentiation inhibiting cell proliferation [9]. To examine the <br /> CYB5D2(D86G) cell culture, stable HeLa cell lines            impact heme-binding CYB5D2 cell proliferation HeLa <br /> vector (EV) ectopically-expressing FLAG-tagged CYB5D2             cells, cell growth curves conducted. In comparison EV <br /> CYB5D2(D86G) generated. CYB5D2 previously                  (control) cells, ectopic CYB5D2 expression reduced HeLa cell <br /> demonstrated display perinuclear localization HeLa cells           proliferation (Figure 4C). However, inhibition HeLa cell <br /> [10]. To reaffirm observation, examined cellular             proliferation cell density dependent, seeding densities ,104 <br /> localization ectopic CYB5D2 CYB5D2(D86G) proteins.                cells/well does result difference cell growth between <br /> Both CYB5D2 CYB5D2(D86G) co-localize ER                     CYB5D2-expressing cells EV cells (data shown). <br /> protein, GRP78 (Figure 4A), suggesting modifying CYB5D2&#8217;s           Moreover, concept ectopic CYB5D2 reduces HeLa cell <br /> heme-binding ability does affect ER localization. To             proliferation strengthened observation ectopic <br />                                                                          expression heme-binding defective CYB5D2(D86G) mutant <br /> confirm stable expression CYB5D2 CYB5D2(D86G) in <br />                                                                          increased cell proliferation (Figure 4C). Therefore, heme-binding <br /> HeLa cells, cell lysates prepared Western blot <br /> analysis performed (Figure 4B). Ectopic CYB5D2                    CYB5D2 required ability regulate HeLa cell <br /> CYB5D2(D86G) expression HeLa cells did induce                 proliferation. <br /> unfolded protein response (UPR) CYB5D2                        The propagation tumorigenic cells soft agar vitro <br /> CYB5D2(D86G) overexpression affected GRP78 protein levels                substitute test tumorigenicity, cell growth anchorage- <br /> (Figure 4B), ER chaperone protein upregulated ER               independent conditions closely associates vivo tumorigenic- <br />                                                                          ity immunocompromised mice [29&#8211;31]. To address whether <br />  <br />  <br /> PLOS ONE | www.plosone.org                                           6                          January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                          CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 3. CYB5D2 binds type b heme, exists oxidized reduced forms. A) Purified recombinant GST-CYB5D2 GST- <br /> CYB5D2(D86G) thrombin-cleaved, uncleaved cleaved (CYB5D2 CYB5D2(D86G), respectively) proteins separated SDS- <br /> PAGE followed Western blot analysis CYB5D2 using anti-CYB5D2 antibody. B) Recombinant GST-free CYB5D2 CYB5D2(D86G) proteins were <br /> oxidised K3Fe(CN)6, followed scanning indicated wavelength range using spectrophotometer. The peak absorbance CYB5D2 was <br /> observed approximately 559 nm. C) Recombinant GST-free CYB5D2 CYB5D2(D86G) proteins reduced sodium dithionite treatment and <br /> scanned absorbance peaks indicated wavelength range. The maximum absorbance peaks oxidized reduced forms of <br /> human CYB5D2 402 nm 420 nm, respectively. <br /> doi:10.1371/journal.pone.0086435.g003 <br />  <br /> heme-binding CYB5D2 contributes HeLa cell anchorage-               fashion. This supported observation stable shRNA- <br /> independent growth, CYB5D2 CYB5D2(D86G)-expressing                   mediated knockdown endogenous CYB5D2 enhanced HeLa <br /> HeLa cells seeded soft agar-containing, serum-supple-            cell proliferation comparison control shRNA (shCTRL) cells <br /> mented media. CYB5D2 expression reduced HeLa cell anchor-                (Figure 5A,B). In addition, knockdown endogenous CYB5D2 in <br /> age-independent growth soft agar, CYB5D2(D86G)                  HeLa cells increased anchorage-independent growth, in <br /> increased colony growth (colony number size) compared             terms colony number size soft agar, compared to <br /> EV cells (Figure 4D,E). Taken together, heme-binding                  shCTRL cells (Figure 5C,D). Collectively, results reveal that <br /> CYB5D2 necessary inhibiting HeLa cell proliferation,           heme-binding activity CYB5D2 required CYB5D2 to <br /> well growth anchorage-independent conditions.                   inhibit HeLa cell growth anchorage-dependent and <br />    The observation ectopic CYB5D2(D86G) significantly               independent conditions. <br /> enhanced HeLa cell proliferation (Figure 4C) colony growth <br /> (Figure 4D,E) suggests CYB5D2(D86G) function to <br /> inhibit endogenous CYB5D2 function dominant-negative <br />  <br />  <br /> PLOS ONE | www.plosone.org                                           7                          January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                               CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 4. CYB5D2 regulates adherent cell proliferation colony growth HeLa cells heme-association dependent manner. <br /> A) HeLa cells infected pLHCX (empty vector; EV), FLAG-CYB5D2/pLHCX, FLAG-CYB5D2(D86G)/pLHCX retrovirus indicated to <br /> generate stable cell lines. Dual immunofluorescence ER-localized GRP78 protein FLAG-tagged CYB5D2 CYB5D2(D86G). Images taken <br /> at 1000X magnification. Scale bar equal 5 mm. B) The expression ectopic CYB5D2 CYB5D2(D86G) proteins cell lysates <br /> demonstrated Western blot analysis. The expression GRP78 actin determined. C) Cell proliferation HeLa cells following ectopic <br /> expression CYB5D2 CYB5D2(D86G). The indicated cell lines seeded 104 cell/well 12-well plates. Cell numbers determined daily <br /> for period 6 days. Experiments conducted quadruplicate, triplicate replicates experiment. Cell numbers determined each <br /> time point presented mean 6 SD. **p,0.01 (two-tailed Student&#8217;s t-test). D) Anchorage-independent growth CYB5D2 CYB5D2(D86G)- <br /> expressing HeLa cells. Representative images soft agar plates (top panels) phase contrast images colonies 50X magnification (bottom <br /> panels). Scale bar equal 200 mm. E) Mean number (left panel) mean diameter (right panel) colonies 10 random fields presented as <br /> mean 6 S.E.M. independent experiments. **p,0.01 (two-tailed Student&#8217;s t-test). <br /> doi:10.1371/journal.pone.0086435.g004 <br />  <br />  <br /> CYB5D2 Regulates CYP51A1 Protein Levels, CYP3A4                              required microsomal cytochrome P450 monooxygenases for <br /> Activity Confers Survival Chemotherapeutic                          catalytic activities [32]. Similarly, CYB5D2 co-localizes with <br />                                                                              ectopic CYPOR protein HeLa cells (Figure 6A), suggesting that <br /> Agents <br />                                                                              CYB5D2 associate CYPOR modulate CYP <br />   PGRMC1 S. cerevisiae homolog, Dap1, interact and <br />                                                                              activities. <br /> regulate cytochrome P450 (CYP) proteins [6,12], enzymes which <br />                                                                                 Dap1 shown regulate stabilize yeast Cyp51A1 <br /> are involved xenobiotic detoxification, pharmaceutical drug <br />                                                                              [4,6], human PGRMC1 shown bind to <br /> metabolism, sterol steroid biosynthesis [11]. <br />                                                                              CYP51A1 (lanosterol demethylase) modulate activity <br /> Furthermore, PGRMC1 shown co-localize bind <br />                                                                              [12,13]. Therefore, examined endogenous levels <br /> with cytochrome P450 reductase (CYPOR) [13], redox partner <br />                                                                              CYP51A1 protein affected following CYB5D2 knockdown <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               8                           January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                              CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 5. CYB5D2 knockdown promotes adherent cell proliferation anchorage-independent growth HeLa cells. A) Western <br /> blot analysis HeLa cells following CYB5D2 shRNA-mediated knockdown (shCYB5D2) compared shRNA control (shCTRL) HeLa cells. B) Cell <br /> proliferation HeLa cells following CYB5D2 knockdown. Experiments conducted quadruplicate, triplicate replicates experiment. <br /> Cell numbers determined time point presented mean 6 SD. **p,0.01 (two-tailed Student&#8217;s t-test). C) Anchorage-independent growth <br /> of shCYB5D2 shCTRL HeLa cells. Representative images soft agar plates (top panels) phase contrast images colonies 50X <br /> magnification (bottom panels). Scale bar equal 200 mm. D) Mean number (left panel) mean diameter (right panel) colonies 10 random <br /> fields evaluated presented mean 6 S.E.M. independent experiments. **p,0.01 (two-tailed Student&#8217;s t-test). <br /> doi:10.1371/journal.pone.0086435.g005 <br />  <br /> in HeLa cells. As shown Figure 6B, CYB5D2 knockdown                      significantly higher CYP3A4 activity levels observed <br /> resulted decreased CYP51A1 protein levels compared                    CYB5D2 knockdown cells (Figure 6D). Taken together, <br /> shCTRL cells. Consistent Dap1 regulating Cyp51A1 stability             CYBD2 co-localizes CYPOR required modulating <br /> and activity, yeast lacking Dap1 higher levels lanosterol        CYP51A1 protein levels CYP3A4 activity HeLa cells. <br /> squalene [6]. Similarly, PRGMC1 knockdown resulted elevated                 Since number CYP proteins involved drug <br /> lanosterol levels HEK293 cells [12,13]. This defect evident          metabolism xenobiotic detoxification [11], investigated <br /> following treatment PGRMC1 knockdown cells mevalo-                  loss CYB5D2 function sensitizes HeLa cells towards <br /> nate, exposed susceptibility increase sterol       chemotherapeutic drug treatment. CYB5D2 shown to <br /> synthesis pathway [12,13]. Mevalonate intermediate             enhance HeLa cell survival etoposide [10]. As shown in <br /> produced series enzymatic reactions leading cholesterol          Figure S2, HeLa cells expressing ectopic CYB5D2 more <br /> synthesis [33]. Therefore, survival capacity CYB5D2                  resistant increasing concentrations paclitaxel (mitotic <br /> knockdown HeLa cells examined following treatment               inhibitor) cisplatin (DNA cross-linking inducer) treatment, <br /> increasing mevalonate concentrations lipoprotein-free                 using concentration range previously shown to <br /> conditions. As shown Figure 6C, CYB5D2 knockdown                         effective reducing HeLa cell viability 48 h treatment <br /> increased susceptibility HeLa cells increasing               [40,41]. Furthermore, CYB5D2(D86G) expression resulted in <br /> mevalonate concentrations, supporting defect lanosterol            increased susceptibility paclitaxel cisplatin treatment <br /> demethylase step mevalonate pathway.                             dose-dependent fashion (Figure S2). These dose response <br />    CYP3A4, abundantly expressed cytochromes              effects clearly dramatic concentration 400 ng/ml for <br /> human liver broad substrate selectivity [34], plays major          paclitaxel cisplatin (Figure S2). Therefore, sensitivity <br /> role metabolism greater 30% clinical drugs                stable HeLa cell lines paclitaxel cisplatin was <br /> [35,36] including paclitaxel [37], cisplatin [38] doxorubicin           evaluated concentration following 24 48 h treatments <br /> [39]. In PGRMC1-deficient cells, enzymatic activity                  (Figure 6E). Treatment CYB5D2-expressing HeLa cells with <br /> CYP3A4 previously shown slightly higher                      paclitaxel cisplatin resulted enhanced cell survival <br /> compared control cells [13]. Upon examining role                  relative EV cells time-dependent fashion (Figure 6E). <br /> CYP5D2 regulating CYP3A4 enzymatic activity, decrease               Conversely, CYB5D2(D86G) HeLa cells demonstrated an <br /> CYP3A4 activity observed following CYB5D2 knockdown                  increased susceptibility paclitaxel cisplatin 24 and <br /> HeLa cells. This reduction evident following transient           48 h, relative EV cells (Figure 6E). Furthermore, CYB5D2 <br /> transfection CYPOR (Figure 6D). While ectopically-transfected            knockdown resulted reduced HeLa cell viability following <br /> CYPOR increased CYP3A4 activity shCTRL cells, activity              paclitaxel cisplatin treatments relative shCTRL cells <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              9                           January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                                CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br />  <br />  <br /> Figure 6. CYB5D2 modulates CYP51A1 protein levels CYP3A4 activity, loss CYB5D2 function rendering HeLa cells <br /> sensitive chemotherapeutic agents. A) Dual immunofluorescence FLAG-tagged CYB5D2 CYPOR-YFP. Stable CYB5D2-expressing <br /> HeLa cells transiently transfected CYPOR-YFP plasmid. Images taken 1000X magnification. Scale bar equal 5 mm. B) Western <br /> blot analysis CYP51A1 protein levels following CYB5D2 shRNA-mediated knockdown (shCYB5D2) HeLa cells compared shRNA control <br /> (shCTRL) cells. C) Mevalonate treatment results reduced survival shCYB5D2 cells compared shCTRL cells. D) CYP3A4 activity reduced in <br /> shCYB5D2 cells compared shCTRL cells, evident following transiently transfecting CYPOR-YFP plasmid (+CYPOR) 24 hours (h). E) <br /> Relative survival HeLa cells expressing ectopic CYB5D2 CYB5D2(D86G) compared vector (EV) control cells (left panels), shRNA <br /> control (shCTRL) CYB5D2 shRNA-mediated knockdown (shCYB5D2) HeLa cells (right panels), following treatment paclitaxel (400 ng/ <br /> ml), cisplatin (400 ng/ml) doxorubicin (10 mM) 24 48 h. At time point, cell survival values normalized dimethylsufloxide <br /> (DMSO)-treated control stable cell line. Relative cell survival values presented mean 6 S.E.M. independent experiments (three <br /> replicates experiment). *p,0.05; **p,0.01 (two-tailed Student&#8217;s t-test). <br /> doi:10.1371/journal.pone.0086435.g006 <br />  <br />  <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               10                           January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                             CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br /> (Figure 6E). Lastly, treatment stable HeLa cell lines         [43]. MAPRs affect multiple cellular processes, including prolif- <br /> doxorubicin (topoisomerase II inhibitor) (10 mM) demonstrated               eration, differentiation, survival genotoxic agents <br /> that CYB5D2 expression conferred greater cell survival, loss          [1,2,43]. Furthermore, CYB5D2 regulates neural cell growth <br /> of function (CYB5D2(D86G) expression CYB5D2 knock-                      survival [9]. Our research establishes functional connection <br /> down) reduced cell survival relative control cells (Figure 6E,           heme-binding CYB5D2 HeLa cell growth under <br /> bottom panels). This doxorubicin concentration consistent               anchorage-dependent independent conditions. Ectopic <br /> with ,75% reduction HeLa cell viability 48 h treatment           CYB5D2 expression reduced HeLa cell proliferation colony <br /> [42]. Taken together, results demonstrate CYB5D2                 growth, expression CYB5D2(D86G) mutant or <br /> confers HeLa cell survival chemotherapeutic agents,           CYB5D2 knockdown increased proliferative capacity and <br /> dependent ability bind heme.                                      growth soft agar (Figures 4 5). As result, effects <br />                                                                             suggest CYB5D2 functions inhibitor cell proliferation, <br /> Heme-binding Required Ectopic CYB5D2 Secretion                       implicates heme-binding required its <br /> in 293T Cells                                                               putative tumor suppressor activity. Interestingly, results are <br />    It recently reported murine CYB5D2 (Neuferri-              opposite reported PGRMC1 shown to <br /> cin) secreted Neuro2a neuroblastoma cells,                 promote MDA-MB-468 breast cancer cell growth presence <br /> Neuferricin knockdown promoting cell survival, proliferation            absence serum, heme-binding defective <br /> inhibiting neurite outgrowth [9]. In addition, exogenous recom-             PGRMC1(D120G) mutant inhibited cell proliferation [44]. <br /> binant Neuferricin, Neuferricin(DHBD) (deletion heme-            Activation ERK signaling, prominent signaling pathway in <br /> binding domain), suppressed cell survival dose-dependent               cancer cells [45], remained unaffected following ectopic expression <br /> fashion [9]. Therefore, examined secretion ectopic                CYBD2 CYB5D2(D86G), following CYB5D2 knock- <br /> CYB5D2 CYB5D2(D86G) HeLa cell conditioned media,                     (data shown). This consistent results reporting no <br /> however, ectopic proteins detected                discernable differences ERK signaling following CYB5D2 <br /> secreted Western blot analysis (data shown). This suggests           overexpression [9]. In addition, differences AKT signal <br /> that secretion CYB5D2 cell line specific, implicates          activation observed, differences expression various <br /> intracellular role mediating proliferative survival              cell cycle regulators (cyclin D1, p27 p21) total IkB-a protein <br /> functions HeLa cells (Figures 4, 5 6). However,                 levels following CYB5D2 knockdown expression ectopic <br /> transiently expressed 293T cells, CYB5D2,                        CYB5D2 CYB5D2(D86G) (Figure S4). As similar trends in <br /> CYB5D2(D86G), readily detected conditioned media                     anchorage-dependent independent growth observed <br /> (Figure S3A, panel), ectopic CYB5D2                following CYB5D2 knockdown ectopic CYB5D2(D86G) <br /> CYB5D2(D86G) proteins expressed comparable levels                expression HeLa cells, loss CYB5D2 function contributes <br /> whole cell lysates (Figure S3A, middle panels). This             increase HeLa cell growth undefined <br /> suggests binding heme required secretion              molecular mechanism. <br /> ectopic CYB5D2 protein 293T cells.                                        The role cytochrome b5 heme-binding (cyt-b5) domain <br />    We subsequently investigated structural elements             containing proteins (yeast Dap1 human PGRMC1) binding <br /> present CYB5D2 (TM, cyt-b5), affect secretion. Upon                  regulating CYP proteins recently investigated <br /> transient transfection 293T cells, CYB5D2(D86G)                [12,13]. Dap1 reported interact yeast P450 <br /> CYB5D2(Dcyt-b5) mutants expressed comparable levels              cytochromes, Cyp51A1 Cyp61A1 [12]. Additionally, <br /> wild-type CYB5D2. However, CYB5D2(DTM) mutant                       PGRMC1 shown associate human <br /> expressed increased level relative mutants               microsomal CYP enzymes: CYP51A1, CYP3A4, CYP21A2, and <br /> (Figure S3B, middle panel). In comparison positive (CYB5D2)              CYP7A1 [12]. PGRMC1 regulates activity CYP51A1 <br /> and negative [CYB5D2(D86G)] controls, CYB5D2(Dcyt-b5)                       (lanosterol demethylase) [12,13], required sterol <br /> protein detected conditioned medium,               production [46,47]. Furthermore, PGRMC1-deficient cells display <br /> CYB5D2(DTM) mutant detected respective conditioned               higher levels lanosterol [12,13], intermediate sterol <br /> medium (Figure S3A, panel). Therefore, CYB5D2(D86G)                 synthesis pathway [47], demonstrate increased sensitivity to <br /> and CYB5D2(Dcyt-b5) mutants, unable bind heme                  mevalonate [12,13]. Similar Dap1, CYB5D2 knockdown <br /> (Figures 1 S1), incapable secreted 293T cells         significantly reduces CYP51A1 protein levels, affecting their <br /> (Figure S3). These observations reveal CYB5D2 ectopically              sensitivity mevalonate treatment implicating <br /> expressed 293T cells secreted, long capable        CYB5D2 protein stabilizing CYP51A1 protein levels. Affyme- <br /> binding heme.                                                               trix DNA microarrays failed detect differences CYP51A1 <br />                                                                             mRNA levels CYB5D2-expressing HeLa cells compared EV <br /> Discussion                                                                  HeLa cells [10], supporting difference CYP51A1 <br />                                                                             protein levels likely regulated level transcription. <br />    CYB5D2 (Neuferricin) heme-binding protein [9],                More recently, PGRMC1 shown interact drug <br /> binds type b heme. Furthermore, CYB5D2 contains cyt-b5                 metabolizing P450 cytochromes (CYP2C2, CYP2C8 and <br /> domain [9], shares homology cyt-b5 domain                  CYP3A4) inhibit activities [13]. Unlike PGRMC1- <br /> containing proteins (Figure 1) required CYB5D2                deficient cells display slightly higher CYP3A4 activity levels <br /> associate heme [9]. In current study, demonstrate          [13], CYB5D2 knockdown reduced CYP3A4 activity, was <br /> the D86 residue, highly conserved amino acid cyt-b5            evident following CYPOR transfection (Figure 6C). There- <br /> region, required CYB5D2 bind heme. This based               fore, PGRMC1 CYB5D2 specifically modulate the <br /> our results showing CYB5D2, CYB5D2(D86G), binds                activities CYP proteins differently. <br /> heme expressed mammalian cells purified                  In conclusion, provide evidence binding heme is <br /> recombinant protein E. coli (Figures 1, 2 3).                      required CYB5D2 regulate HeLa cell growth confer its <br />    CYB5D2 belongs family membrane-associated                      survival treatment chemotherapeutic agents, paclitaxel, <br /> progesterone receptors (MAPRs) possess cyt-b5 domain                cisplatin doxorubicin. Furthermore, study to <br />  <br />  <br /> PLOS ONE | www.plosone.org                                             11                          January 2014 | Volume 9 | Issue 1 | e86435 <br />                                                                                                                CYB5D2 Heme-Binding Regulates Growth Survival <br />  <br />  <br /> report CYB5D2 regulates activities cytochrome                              Figure S3 Heme-binding defective mutants CYB5D2 <br /> P450 proteins, CYP51A1 CYP3A4, involved                                   undergo cell secretion following ectopic expres- <br /> sterol synthesis drug metabolism, respectively. As                         sion 293T cells. A) CYB5D2 CYB5D2(D86G) were <br /> previously reported CYB5D2 does impact core                                   transiently expressed 48 hours 293T cells. Cell lysates and <br /> processes apoptosis HeLa cells [10], intriguing                        conditioned medium analysed Western blot CYB5D2 <br /> further decipher survival mechanisms regulated CYB5D2.                              actin expression. B) The secretion wild-type CYB5D2 and <br /> Interestingly, CYB5D2 PGRMC1 mediate opposing effects                                  domain deletion (DTM Dcyt-b5) mutants also <br /> on cell proliferation, possibly intracellular (ER-localized)                     analyzed Western blot. Blots probed anti-HA <br /> functions associated heme-binding including CYP activities                         antibody. * indicates background bands. <br /> a CYPOR-mediated fashion. We currently investigating                                   (TIF) <br /> additional CYP proteins activity regulated by <br />                                                                                            Figure S4 Examination cell cycle regulators, IkB-a <br /> CYB5D2. Overall, emerging role CYB5D2 protein that <br />                                                                                            protein levels, AKT signal activation CYB5D2- <br /> confers survival chemotherapeutic agents makes an <br />                                                                                            expressing CYB5D2 loss-of-function HeLa cells. <br /> attractive target future therapies. <br />                                                                                            Western blot analysis vector (EV), CYB5D2 and <br />                                                                                            CYB5D2(D86G)-expressing HeLa cells (left panels), shRNA <br /> Supporting Information                                                                     control (shCTRL) CYB5D2 shRNA-mediated knockdown <br /> Figure S1 Characterization CYB5D2-mediated heme-                                        (shCYB5D2) HeLa cells (right panels). Expression cyclin D1, <br /> binding. A) Schematic representation CYB5D2,                                            p21, p27 IkB-a proteins examined. AKT activation was <br /> CYB5D2(D86G) mutants deletions (D)                                      determined examining phosphorylation AKT the <br /> transmembrane (TM) cyt-b5 domains, ability                             Ser473 residue (AKT-P). Actin used loading control. <br /> to bind heme. B) Transient expression indicated                                     (TIF) <br /> complementary DNA (cDNA) domain deletion mutants 293T                                   Table S1 Primers PCR conditions used construct <br /> cells (top panel). The heme-binding capacity analyzed                               CYB5D2 mutants. <br /> hemin-agarose precipitation (bottom panel).                                                (DOC) <br /> (TIF) <br /> Figure S2     Dose-dependent response curves following                                     Acknowledgments <br /> treatment HeLa cells paclitaxel cisplatin.                                     We like acknowledge preliminary work carried Dr. L. <br /> Relative survival paclitaxel cisplatin-treated HeLa cells                           He. We like thank Dr. F. Wei R. Carlisle providing <br /> expressing ectopic CYB5D2 CYB5D2(D86G) compared                                      technical assistance. We like thank Dr. B. Kemper <br /> empty vector (EV) control cells. Cells treated increasing                        (University Illinois, USA) providing CYPOR-YFP construct, <br /> concentrations paclitaxel cisplatin 24 hours (h) (left panels)                   Dr. H. Duivenvoorden (Hamilton Centre Kidney Research, <br /> or 48 h (right panels). Cell survival values normalized                          Hamilton, ON, Canada) providing cisplatin used study. <br /> dimethylsufloxide (DMSO)-treated control stable cell line. <br /> Relative cell survival values presented mean 6 S.E.M.                            Author Contributions <br /> three independent experiments (three replicates experi-                            Conceived designed experiments: AB APR. Performed the <br /> ment). *p,0.05; **p,0.01 (two-tailed Student&#8217;s t-test).                                    experiments: AB APR. Analyzed data: AB APR. Contributed <br /> (TIF)                                                                                      reagents/materials/analysis tools: AB APR. Wrote paper: AB APR. <br />  <br /> References <br />  1. Rohe HJ, Ahmed IS, Twist KE, Craven RJ (2009) PGRMC1 (progesterone                     12. Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, et al. (2007) Dap1/ <br />     receptor membrane component 1): targetable protein multiple functions               PGRMC1 binds regulates cytochrome P450 enzymes. Cell Metab 5: 143&#8211; <br />     steroid signaling, P450 activation drug binding. Pharmacol Ther 121: 14&#8211;            149. <br />     19.                                                                                    13. Szczesna-Skorupa E, Kemper B (2011) Progesterone receptor membrane <br />  2. Cahill MA (2007) Progesterone receptor membrane component 1: integrative                component 1 inhibits activity drug-metabolizing cytochromes P450 and <br />     review. J Steroid Biochem Mol Biol 105: 16&#8211;36.                                             binds cytochrome P450 reductase. Mol Pharmacol 79: 340&#8211;350. <br />  3. Losel RM, Besong D, Peluso JJ, Wehling M (2008) Progesterone receptor                  14. Tang D, Chun AC, Zhang M, Wang JH (1997) Cyclin-dependent kinase 5 <br />     membrane component 1&#8211;many tasks versatile protein. Steroids 73: 929&#8211;                 (Cdk5) activation domain neuronal Cdk5 activator. Evidence existence <br />     934.                                                                                       cyclin fold neuronal Cdk5a activator. J Biol Chem 272: 12318&#8211;12327. <br />  4. Craven RJ, Mallory JC, Hand RA (2007) Regulation iron homeostasis                   15. Berry EA, Trumpower BL (1987) Simultaneous determination hemes a, b, <br />     mediated heme-binding protein Dap1 (damage resistance protein 1)                c pyridine hemochrome spectra. Anal Biochem 161: 1&#8211;15. <br />     P450 protein Erg11/Cyp51. J Biol Chem 282: 36543&#8211;36551.                            16. Thomas PE, Ryan D, Levin W (1976) An improved staining procedure the <br />  5. Hand RA, Jia N, Bard M, Craven RJ (2003) Saccharomyces cerevisiae Dap1p,                 detection peroxidase activity cytochrome P-450 sodium dodecyl <br />     novel DNA damage response protein related mammalian membrane- <br />                                                                                                sulfate polyacrylamide gels. Anal Biochem 75: 168&#8211;176. <br />     associated progesterone receptor. Eukaryot Cell 2: 306&#8211;317. <br />                                                                                            17. Kimura I, Nakayama Y, Yamauchi H, Konishi M, Miyake A, et al. (2008) <br />  6. Mallory JC, Crudden G, Johnson BL, Mo C, Pierson CA, et al. (2005) Dap1p, a <br />                                                                                                Neurotrophic activity neudesin, novel extracellular heme-binding protein, is <br />     heme-binding protein regulates cytochrome P450 protein Erg11p/ <br />                                                                                                dependent binding heme cytochrome b5-like heme/steroid- <br />     Cyp51p Saccharomyces cerevisiae. Mol Cell Biol 25: 1669&#8211;1679. <br />  7. Crudden G, Chitti RE, Craven RJ (2006) Hpr6 (heme-1 domain protein)                        binding domain. J Biol Chem 283: 4323&#8211;4331. <br />     regulates susceptibility cancer cells chemotherapeutic drugs.                18. Wojtowicz H, Wojaczynski J, Olczak M, Kroliczewski J, Latos-Grazynski L, et <br />     J Pharmacol Exp Ther 316: 448&#8211;455.                                                         al. (2009) Heme environment HmuY, heme-binding protein of <br />  8. Min L, Strushkevich NV, Harnastai IN, Iwamoto H, Gilep AA, et al. (2005)                   <span id='am-74' about='obo:NCBITaxon_836' typeof='owl:Thing obo:NCBITaxon_171551 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_200643 obo:NCBITaxon_171549 obo:NCBITaxon_976 obo:NCBITaxon_68336'><span id='am-75' property="oboInOwl:hasDbXref" content="PMID:8186083" datatype="xsd:string"></span><span id='am-76' property="rdfs:label" content="Porphyromonas" datatype="xsd:string"></span><span id='am-77' property="oboInOwl:hasDbXref" content="PMID:15774632" datatype="xsd:string"></span><span id='am-78' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasDbXref" content="PMID:8590687" datatype="xsd:string"></span><span id='am-80'  ></span><span id='am-81' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span>Porphyromonas</span> gingivalis. Biochem Biophys Res Commun 383: 178&#8211;182. <br />     Molecular identification adrenal inner zone antigen heme-binding               19. Nakamoto SS, Hamel P, Merchant S (2000) Assembly chloroplast <br />     protein. Febs J 272: 5832&#8211;5843.                                                            cytochromes b c. Biochimie 82: 603&#8211;614. <br />  9. Kimura I, Nakayama Y, Konishi M, Kobayashi T, Mori M, et al. (2010)                    20. Olczak T, Dixon DW, Genco CA (2001) Binding specificity the <br />     Neuferricin, novel extracellular heme-binding protein, promotes neurogenesis.            <span id='am-82' about='obo:NCBITaxon_837' typeof='owl:Thing obo:NCBITaxon_171551 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_200643 obo:NCBITaxon_836 obo:NCBITaxon_171549 obo:NCBITaxon_976 obo:NCBITaxon_68336'><span id='am-83'  ></span><span id='am-84' property="rdfs:label" content="Porphyromonas gingivalis" datatype="xsd:string"></span><span id='am-85' property="oboInOwl:hasRelatedSynonym" content="Bacteroides gingivalis" datatype="xsd:string"></span><span id='am-86' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Porphyromonas gingivalis</span> heme hemoglobin receptor HmuR, gingipain <br />     J Neurochem 112: 1156&#8211;1167.      <br /> </body></html>